Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus

详细信息    查看全文

• 作者：Hilary A Robbins (17)
  Yan Li (17) (18)
  Carolina Porras (19)
  Michael Pawlita (20)
  Arpita Ghosh (21)
  Ana Cecilia Rodriguez (19)
  Mark Schiffman (17)
  Sholom Wacholder (17)
  Troy J Kemp (22)
  Paula Gonzalez (19) (23)
  John Schiller (24)
  Douglas Lowy (24)
  Mark Esser (25)
  Katie Matys (26)
  Wim Quint (27)
  Leen-Jan van Doorn (27)
  Rolando Herrero (19) (23)
  Ligia A Pinto (22)
  Allan Hildesheim (17)
  Tim Waterboer (20)
  Mahboobeh Safaeian (17)
  
• 刊名：BMC Infectious Diseases
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：348 KB
• 参考文献：1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. / J Pathol 1999, 189:12-9. CrossRef
  2. Lowy DR, Schiller JT: Reducing HPV-associated cancer globally. / Cancer Prev Res (Phila) 2012, 5:18-3. CrossRef
  3. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R: Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. / J Natl Cancer Inst 2008, 100:513-17. CrossRef
  4. Stanley M: Immune responses to human papillomavirus. / Vaccine 2006,24(Suppl 1):S16-S22. CrossRef
  5. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA: Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. / J Infect Dis 2000, 181:1911-919. CrossRef
  6. Wentzensen N, Rodriguez AC, Viscidi R, Herrero R, Hildesheim A, Ghosh A, Morales J, Wacholder S, Guillen D, Alfaro M, Safaeian M, Burk RD, Schiffman M: A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. / J Infect Dis 2011, 204:94-02. CrossRef
  7. Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, Herrero R, Hildesheim A: Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. / J Natl Cancer Inst 2010, 102:1653-662. CrossRef
  8. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. / Lancet 2004, 364:1757-765. CrossRef
  9. Schiller JT, Lowy DR: Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. / J Infect Dis 2009, 200:166-71. CrossRef
  10. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA: Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. / Hum Vaccin 2008, 4:425-34. CrossRef
  11. Coseo SE, Porras C, Dodd LE, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Sherman ME, Jimenez S, Solomon D, Bougelet C, van Doorn LJ, Quint W, Safaeian M: Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure. / Sex Transm Dis 2011, 38:976-82. CrossRef
  12. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT: Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. / Clin Diagn Lab Immunol 2003, 10:108-15.
  13. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kruger KS, Lowy DR, Schiller JT: Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. / Virology 2004, 321:205-16. CrossRef
  14. Sehr P, Muller M, Hopfl R, Widschwendter A, Pawlita M: HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. / J Virol Methods 2002, 106:61-0. CrossRef
  15. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, Templin MF, Pawlita M: Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. / Clin Chem 2005, 51:1845-853. CrossRef
  16. Rizk RZ, Christensen ND, Michael KM, Muller M, Sehr P, Waterboer T, Pawlita M: Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. / J Gen Virol 2008, 89:117-29. CrossRef
  17. Sitas F, Egger S, Urban MI, Taylor PR, Abnet CC, Boffetta P, O’Connell DL, Whiteman DC, Brennan P, Malekzadeh R, Pawlita M, Dawsey SM, Waterboer T: InterSCOPE study: associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. / J Natl Cancer Inst 2012, 104:147-58. CrossRef
  18. Farzan SF, Waterboer T, Gui J, Nelson HH, Li Z, Michael KM, Perry AE, Spencer SK, Demidenko E, Green AC, Pawlita M, Karagas MR: Cutaneous alpha, beta and gamma human papillomaviruses in relation to squamous cell carcinoma of the skin: a population-based study. / Int J Cancer 2013,133(7):1713-720. CrossRef
  19. Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S, Gaborieau V, Marron M, Lagiou P, Ahrens W, Holcatova I, Merletti F, Kjaerheim K, Talamini R, Simonato L, Castellsague X, Macfarlane TV, Biggs AM, Thakker N, Znaor A, Thomson P, Canova C, Conway DI, Healy CM, Tommasino M, Pawlita M, Brennan P: Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. / J Natl Cancer Inst 2013, 105:536-45. CrossRef
  20. Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D, Tjonneland A, Overvad K, Quiros JR, Gonzalez CA, Sanchez MJ, Larranaga N, Navarro C, Barricarte A, Travis RC, Khaw KT, Wareham N, Trichopoulou A, Lagiou P, Trichopoulos D, Peeters PH, Panico S, Masala G, Grioni S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Laurell G, Hallmans G, Manjer J, / et al.: Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. / J Clin Oncol 2013, 31:2708-715. CrossRef
  21. Michael KM, Waterboer T, Sehr P, Rother A, Reidel U, Boeing H, Bravo IG, Schlehofer J, Gartner BC, Pawlita M: Seroprevalence of 34 human papillomavirus types in the German general population. / PLoS Pathog 2008, 4:e1000091. CrossRef
  22. Dondog B, Clifford GM, Vaccarella S, Waterboer T, Unurjargal D, Avirmed D, Enkhtuya S, Kommoss F, Wentzensen N, Snijders PJ, Meijer CJ, Franceschi S, Pawlita M: Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. / Cancer Epidemiol Biomarkers Prev 2008, 17:1731-738. CrossRef
  23. Paaso AE, Louvanto K, Syrjanen KJ, Waterboer T, Grenman SE, Pawlita M, Syrjanen SM: Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa. / J Gen Virol 2011, 92:2034-046. CrossRef
  24. Wilson LE, Pawlita M, Castle PE, Waterboer T, Sahasrabuddhe V, Gravitt PE, Schiffman M, Wentzensen N: Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL triage study. / Int J Cancer 2013,133(9):2172-181. CrossRef
  25. Scherpenisse M, Schepp RM, Mollers M, Mooij SH, Meijer CJ, Berbers GA, van der Klis FR: A comparison of different assays to assess HPV16 and 18-specific antibodies after HPV infection and vaccination. / Clin Vaccine Immunol 2013,20(8):1329-332. CrossRef
  26. Sehr P, Rubio I, Seitz H, Putzker K, Ribeiro-Muller L, Pawlita M, Muller M: High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. / PLoS One 2013, 8:e75677. CrossRef
  27. Liang C, Marsit CJ, McClean MD, Nelson HH, Christensen BC, Haddad RI, Clark JR, Wein RO, Grillone GA, Houseman EA, Halec G, Waterboer T, Pawlita M, Krane JF, Kelsey KT: Biomarkers of HPV in head and neck squamous cell carcinoma. / Cancer Res 2012, 72:5004-013. CrossRef
  28. Herrero R, Hildesheim A, Rodriguez AC, Wacholder S, Bratti C, Solomon D, Gonzalez P, Porras C, Jimenez S, Guillen D, Morales J, Alfaro M, Cyr J, Morrisey K, Estrada Y, Cortes B, Morera LA, Freer E, Schussler J, Schiller J, Lowy D, Schiffman M: Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. / Vaccine 2008, 26:4795-808. CrossRef
  29. Safaeian M, Ghosh A, Porras C, Lin SW, Rodriguez AC, Schiffman M, Wacholder S, Kemp T, Gonzalez P, Wentzensen N, Esser M, Meuree A, Matys K, Quint W, van Doorn LJ, Sherman ME, Herrero R, Pinto LA, Hildesheim A: Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials. / Cancer Epidemiol Biomarkers Prev 2012, 21:1547-554. CrossRef
  30. Waterboer T, Sehr P, Pawlita M: Suppression of non-specific binding in serological Luminex assays. / J Immunol Methods 2006, 309:200-04. CrossRef
  31. Clifford GM, Shin HR, Oh JK, Waterboer T, Ju YH, Vaccarella S, Quint W, Pawlita M, Franceschi S: Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. / Cancer Epidemiol Biomarkers Prev 2007, 16:1874-879. CrossRef
  32. Waterboer T, Dondog B, Michael KM, Michel A, Schmitt M, Vaccarella S, Franceschi S, Clifford G, Pawlita M: Dried blood spot samples for seroepidemiology of infections with human papillomaviruses, Helicobacter pylori, Hepatitis C Virus, and JC Virus. / Cancer Epidemiol Biomarkers Prev 2012, 21:287-93. CrossRef
  33. Dias D, Van DJ, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, Chirmule N, Barr E, Jansen KU, Esser MT: Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. / Clin Diagn Lab Immunol 2005, 12:959-69.
  34. Kemp TJ, Garcia-Pineres A, Falk RT, Poncelet S, Dessy F, Giannini SL, Rodriguez AC, Porras C, Herrero R, Hildesheim A, Pinto LA: Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. / Vaccine 2008, 26:3608-616. CrossRef
  35. Kleter B, van Doorn LJ, ter SJ, Schrauwen L, van KK, Burger M, ter HB, Quint W: Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. / Am J Pathol 1998, 153:1731-739. CrossRef
  36. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter SJ, Lindeman J, ter HB, Burger M, Quint W: Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. / J Clin Microbiol 1999, 37:2508-517.
  37. Coseo S, Porras C, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Wang SS, Sherman ME, Jimenez S, Solomon D, Bougelet C, van Doorn LJ, Quint W, Safaeian M: Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. / Sex Transm Dis 2010, 37:706-14. CrossRef
  38. Silins I, Kallings I, Dillner J: Correlates of the spread of human papillomavirus infection. / Cancer Epidemiol Biomarkers Prev 2000, 9:953-59.
  39. Szklo M, Nieto FJ: Quality Assurance and Control. In / Epidemiology: Beyond the Basics. Gaithersburg, MD: Aspen Publishers, Inc; 2000:375-76.
  40. Syrjanen S, Waterboer T, Sarkola M, Michael K, Rintala M, Syrjanen K, Grenman S, Pawlita M: Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. / J Gen Virol 2009, 90:1515-526. CrossRef
  41. Lin SW, Ghosh A, Porras C, Markt SC, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Pinto LA, Gonzalez P, Wentzensen N, Esser MT, Matys K, Meuree A, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Safaeian M: HPV16 Seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. / PLoS One 2013, 8:e53067. CrossRef
  42. Wilson L, Pawlita M, Castle PE, Waterboer T, Sahasrabuddhe V, Gravitt PE, Schiffman M, Wentzensen N: Seroprevalence of eight oncogenic human papillomaviruses and acquired immunity against re-infection. / J Infect Dis 2014. in press
  43. Antonsson A, Pawlita M, Feltkamp MC, Bouwes Bavinck JN, Euvrard S, Harwood CA, Naldi L, Nindl I, Proby CM, Neale RE, Waterboer T: Longitudinal study of seroprevalence and serostability of the human polyomaviruses JCV and BKV in organ transplant recipients. / J Med Virol 2013, 85:327-35. CrossRef
  44. Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC: Seroprevalence of human papillomavirus type 16 infection in the United States. / J Infect Dis 2002, 186:1396-402. CrossRef
  45. The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2334/14/120/prepub
  
• 作者单位：Hilary A Robbins (17)
  Yan Li (17) (18)
  Carolina Porras (19)
  Michael Pawlita (20)
  Arpita Ghosh (21)
  Ana Cecilia Rodriguez (19)
  Mark Schiffman (17)
  Sholom Wacholder (17)
  Troy J Kemp (22)
  Paula Gonzalez (19) (23)
  John Schiller (24)
  Douglas Lowy (24)
  Mark Esser (25)
  Katie Matys (26)
  Wim Quint (27)
  Leen-Jan van Doorn (27)
  Rolando Herrero (19) (23)
  Ligia A Pinto (22)
  Allan Hildesheim (17)
  Tim Waterboer (20)
  Mahboobeh Safaeian (17)
  
  17. Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, Maryland, USA
  18. Joint Program for Survey Methodology, University of Maryland, College Park, Maryland, USA
  19. Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica
  20. German Cancer Research Center (DKFZ), Heidelberg, Germany
  21. Public Health Foundation of India, New Delhi, India
  22. HPV Immunology Laboratory, SAIC-Frederick Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA
  23. International Agency for Research on Cancer, Lyon, France
  24. Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
  25. MedImmune, Gaithersburg, Maryland, USA
  26. PPD Vaccines and Biologics Center of Excellence, Wayne, Pennsylvania, USA
  27. DDL Diagnostic Laboratory, Rijswijk, Netherlands
  
• ISSN：1471-2334

文摘

Background Several assays are used to measure type-specific serological responses to human papillomavirus (HPV), including the bead-based glutathione S-transferase (GST)-L1 multiplex serology assay and virus-like particle (VLP)-based ELISA. We evaluated the high-throughput GST-L1, which is increasingly used in epidemiologic research, as a measure of cumulative HPV infection and future immune protection among HPV-unvaccinated women. Methods We tested enrollment sera from participants in the control arm of the Costa Rica Vaccine Trial (n--88) for HPV16 and HPV18 using GST-L1, VLP-ELISA, and two assays that measure neutralizing antibodies (cLIA and SEAP-NA). With statistical adjustment for sampling, we compared GST-L1 serostatus to established HPV seropositivity correlates and incident cervical HPV infection using odds ratios. We further compared GST-L1 to VLP-ELISA using pair-wise agreement statistics and by defining alternate assay cutoffs. Results Odds of HPV16 GST-L1 seropositivity increased with enrollment age (OR--.20 per year, 95%CI 1.03-1.40) and lifetime number of sexual partners (OR--.06 per partner, 95%CI 1.49-2.83), with similar results for HPV18. GST-L1 seropositivity did not indicate protection from incident infection over 4?years of follow-up (HPV16 adjusted OR--.72, 95%CI 0.95-3.13; HPV18 adjusted OR--.38, 95%CI 0.12-1.23). Seroprevalence by GST-L1 (HPV16 and HPV18, respectively) was 5.0% and 5.2%, compared to 19.4% and 23.8% by VLP-ELISA, giving positive agreement of 39.2% and 20.8%. Lowering GST-L1 seropositivity cutoffs improved GST-L1/VLP-ELISA positive agreement to 68.6% (HPV16) and 61.5% (HPV18). Conclusions Our data support GST-L1 as a marker of cumulative HPV infection, but not immune protection. At lower seropositivity cutoffs, GST-L1 better approximates VLP-ELISA.